A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Chronic Hepatitis C Virus Genotype 1 Infection.

Trial Profile

A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Chronic Hepatitis C Virus Genotype 1 Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Beclabuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HEPCAT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Oct 2013 Results will be presented at the 64th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD) according to a Bristol-Myers Squibb media release.
    • 04 Apr 2012 Results will be presented at EASL-2012 according to a Bristol-Myers Squibb media release.
    • 18 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top